InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$59.75

2026-10-16

Market Cap

$122.1B

Volume

12.8M

52-Wk High

$68.64

52-Wk Low

$42.52

Trailing PE

13.2

P/S

2.48

Gross Margin

70.2%

Net Margin

18.9%

ROE

47%

ROIC

15%

Piotroski

7/9

Altman Z

2.7

1-Yr Return

+43.8%

5-Yr Return

+65.5%

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

SectorHealthcareIndustryDrug Manufacturers - GeneralExchangeNYSEMarket Cap$122.1BEmployees32,500 (SEC-filed)CEOChristopher BoernerIPO1972-06-01CountryUS

Route 206 & Province Line Road, Princeton, NJ 08543 · Tel 609 252 4621 · bms.com

INSIDERSTREET SCORE68 / 100Street mean $65.54 (13 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$2M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · BMY +43.8% · S&P 500 +15.9% · spread +28.0pp

7 Years vs S&P 500 · BMY +65.5% · S&P 500 +189.9% · spread -124.4pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE68of 100

Score Breakdown

Profitability	89/100
Growth	63/100
Momentum	87/100
Quality	80/100
Earnings Quality	71/100
Balance Sheet	53/100
Value	67/100
Risk (safety)	65/100
Overall	67.7/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
PFE	46
GILD	44
AMGN	67
AZN	71
NVS	65
MRK	49
BMY	68

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 68 in 26 Q2, latest 68 — +0 since. Fell in 1 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY68 / 100IS Score 67.7 / 100 · +0.0 from peak of 68

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBEARISHTechnical Score 34 / 100 · Power -33 · 7 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 68, price structure 34 out of 100, so the business reads better than the price does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 67.7	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 67 → 62 → 66 → 68	the direction matters more than the level
Technical vote share back above 50%	now 18%	price structure no longer broken
Institutional holder count rises two quarters running	peak 2,545 → now 2,534	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score2 of 4top 13% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)0 buysnone disclosed

Insider Buys (180d)0none disclosed

ETF Funds (30d)1752 up / 1323 downnet +429 funds

Institutions Added (13F)-11managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 2,545 · latest 2,534 (-11 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	2,534	1744.0M	$96.5B	85.4%
2026 Q1	2,545	1619.8M	$95.0B	79.3%
2025 Q4	2,466	1642.0M	$86.4B	80.4%
2025 Q3	2,276	1587.8M	$70.2B	77.8%
2025 Q2	2,305	1646.8M	$75.6B	80.6%
2025 Q1	2,490	1634.4M	$98.3B	80.0%
2024 Q4	2,496	1599.6M	$88.9B	78.3%
2024 Q3	2,269	1549.1M	$77.9B	75.9%
2024 Q2	2,161	1536.5M	$62.5B	75.2%
2024 Q1	2,344	1562.3M	$82.8B	76.5%
2023 Q4	2,371	1549.5M	$78.6B	75.9%
2023 Q3	2,397	1570.8M	$90.7B	76.9%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Gallman Cari	EVP, General Counsel	2026-10-02	EXERCISE	4,559	—	18,208
Gallman Cari	EVP, General Counsel	2026-10-02	TAX W/H	2,332	$0.14M	15,876
Gallman Cari	EVP, General Counsel	2026-10-02	EXERCISE	4,559	—	0
Yale Phyllis R	director	2026-09-30	A-Award	561	—	45,980
Samuels Theodore R. Ii	director	2026-09-30	A-Award	821	—	71,859
Rice Derica W	director	2026-09-30	A-Award	621	—	42,085
Mcmullen Michael R.	director	2026-09-30	A-Award	561	—	17,051
Arduini Peter J	director	2026-09-30	A-Award	561	—	74,077

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	4	36,749	$2.3M	Counted
M — Exercises (paired A/D)	41	299,974	$1.1M	None — mechanics
F — Tax withholding	42	107,266	$6.6M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$2.3M4 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Member	Chamber	Trade	Size band	Traded	Disclosed
Mike Kelly	House	SELL	$15,001 - $50,000	2026-05-07	2026-06-12
Mike Kelly	House	SELL	$15,001 - $50,000	2026-05-07	2026-06-12
Mike Kelly	House	SELL	$15,001 - $50,000	2026-05-06	2026-06-12
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2025-04-15	2026-08-05
Thomas Hawley Tuberville	Senate	SELL	$1,001 - $15,000	2025-04-15	2026-08-05
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2025-04-15	2025-05-15

House 12-Mo18 trades5 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

13F Filers (last complete Q)2,545

13F Shares1.62B79.3% of shares out

New / Closed271 / 148positions, QoQ

Increased / Reduced1,065 / 880positions, QoQ

Put/Call (13F)0.92option positions

Free Float99.8%2.04B sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Artemis Investment Management Llp	2.8M	$176M
Wealth Enhancement Advisory Servic	2.1M	$104M
Fort Washington Investment Advisor	1.7M	$107M
Douglas Lane & Associates, Llc	1.5M	$94M
Fjarde Ap-Fonden /Fourth Swedish N	877,685	$55M
Vontobel Holding Ltd.	767,237	$48M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.2%	$4.0B
VTI	0.2%	$4.0B
VSMPX	0.2%	$4.0B
VTSAX	0.2%	$4.0B
SCHD	3.0%	$3.4B
VOO	0.2%	$3.3B

13F Filers Holding BMY — quarterly

Institutional Put/Call — quarterly

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session39.3%2026-10-15

20-Day Avg44.2%50-day 48.6%

TrendFalling20d vs 50d

By Market CenterQ: 39% · N: 47% · B: 44%latest session

Weekly Notional ($B)

Where BMY Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	9.9M	83 sh
Ebxl Level Ats	6.5M	48 sh
Ubsa Ubs Ats	6.4M	68 sh
Mstx Ms Trajectory Cross (Ats-1)	6.0M	102 sh
Pure Purestream	4.0M	50 sh
Sgmt Sigma X2	3.9M	76 sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Where a dollar of Bristol-Myers Squibb Company revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$33.3B	97%
Other Region	$1.1B	3%

BMY (live moat model)Peer median: PFE · GILD · AMGN · AZN · NVS

Component scores from the live moat model. Peer median illustrative.

Moat score 56/100 — Narrow; primary source Efficient Scale.

3.8 · Employees (SEC filings)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Officer	Title
Christopher S. Boerner	Chief Executive Officer & Chairman
David V. Elkins	Executive Vice President & Chief Financial Officer
Adam Lenkowsky	Executive Vice President & Chief Commercialization Officer
Greg Meyers	Executive Vice President and Chief Digital & Technology Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

Quarterly EPS — Actual vs. Consensus

Beats (>2%)6 of 6recent quarters

Avg Surprise+17.2%

Next Report2026-10-29

Income Quality1.38OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Profit Margins (%)

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+9.1%	-0.5%	-2.5%	+7.3%	-0.2%
Gross profit	+23.3%	-1.0%	-4.3%	+8.2%	+18.8%
Operating income	+112.4%	-2.8%	-8.6%	+14.0%	+31.5%
Net income	-177.8%	-9.5%	+26.8%	-211.5%	-178.8%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	46.4	46.2	45.0	48.3	48.2
Cost of revenue	19.6	19.7	19.6	20.9	15.6
Gross profit	26.8	26.5	25.4	27.4	32.6
R&D expense	9.5	9.4	9.2	9.8	9.6
SG&A expense	7.7	7.8	7.7	7.9	7.2
Operating income	9.5	9.3	8.5	9.7	12.7
EBITDA	20.1	19.2	19.4	3.2	14.5
D&A	10.7	10.3	9.8	9.6	3.9
Pretax income	8.1	7.7	8.4	-8.4	9.3
Income tax	1.1	1.4	0.4	0.6	2.3
Net income	7.0	6.3	8.0	-8.9	7.1
Diluted EPS ($)	3.12	2.95	3.86	-4.41	3.45
Diluted shares (M)	2,245	2,146	2,078	2,027	2,041

Operating CF$14B

CapEx$1B

Free cash flow$13B

SBC$1B

Buybacks$0B

Net cash change$-0B

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	9.1	11.5	10.3	10.2
ST investments	0.1	0.8	0.5	0.5
Receivables (net)	13.9	15.3	14.4	14.5
Total current assets	27.3	31.8	29.8	29.4
PP&E (net)	7.5	8.0	8.4	9.1
Goodwill + intangibles	57.5	48.7	45.4	40.9
Total assets	96.8	95.2	92.6	90.0
Accounts payable	3.0	3.3	3.6	3.6
Short-term debt	4.3	3.1	2.0	2.3
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	21.9	22.3	23.8	23.4
Long-term debt	35.1	36.7	47.6	42.9
Total liabilities	65.7	65.7	76.2	71.5
Shareholders' equity	31.1	29.5	16.4	18.5

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	6.3	8.0	(8.9)	7.1
D&A	10.3	9.8	9.6	4.0
Stock-based compensation	0.5	0.5	0.5	0.6
Working capital change	(2.2)	(1.9)	0.8	(0.5)
Operating cash flow	13.1	13.9	15.2	14.2
Capital expenditures	(1.1)	(1.2)	(1.2)	(1.3)
Investing cash flow	(1.1)	(2.3)	(21.4)	(4.1)
Buybacks	(8.0)	(5.2)	0.0	0.0
Dividends paid	(4.6)	(4.7)	(4.9)	(5.0)
Debt issuance / (repay)	(5.3)	0.5	10.1	(5.2)
Financing cash flow	(17.0)	(9.4)	5.1	(10.3)
Free cash flow	11.9	12.7	13.9	12.8

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	19.0%	18.9%	26.5%	-39.1%	40.5%	47%
ROA	6.1%	6.1%	8.4%	-9.5%	7.7%	10.6%
ROIC	10.4%	12.3%	13.7%	12.5%	17.5%	15.4%
Gross margin	57.7%	57.4%	56.3%	56.8%	67.6%	70.2%
Operating margin	20.6%	20.1%	18.8%	20.0%	26.3%	28.1%
Net margin	15.1%	13.7%	17.8%	-18.5%	14.6%	18.9%
EBITDA margin	43.4%	41.6%	43.0%	6.6%	30.2%	34.2%
FCF margin	32.8%	25.9%	28.1%	28.9%	26.7%	—
VALUATION
P/E	16.80	21.15	11.79	-12.27	15.43	13.2
P/B	3.27	4.31	3.21	6.72	5.89	5.5
P/S	2.53	2.90	2.10	2.27	2.26	2.48
P/FCF	7.71	11.20	7.48	7.87	8.47	10.7
EV/EBITDA	7.25	8.60	6.39	47.38	9.99	9.3
EV/Revenue	3.14	3.58	2.75	3.11	3.01	3.2
Earnings yield	6.0%	4.7%	8.5%	-8.2%	6.5%	7.61%
FCF yield	13.0%	8.9%	13.4%	12.7%	11.8%	9.37%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.52	1.25	1.43	1.25	1.26	1.53
Quick ratio	1.43	1.14	1.31	1.15	1.14	1.38
Debt / equity	1.27	1.31	1.41	3.13	2.55	1.93
Debt / assets	41.7%	42.1%	43.6%	55.3%	52.4%	49.2%
Net debt / EBITDA	1.41	1.64	1.51	12.73	2.51	2.05
Interest coverage	7.07	7.26	8.22	-3.30	7.08	—

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.41	0.45	0.47	0.51	0.53	0.56
Receivables turnover	6.10	5.72	5.28	5.40	5.18	4.7
DSO (days)	60	64	69	68	70	78
DPO (days)	53	56	59	60	84	103
Cash conversion cycle	46	49	57	53	48	43
GROWTH (YoY)
Revenue growth	9.1%	-0.5%	-2.5%	7.3%	-0.2%	—
Net income growth	177.6%	-9.5%	26.8%	-211.5%	178.8%	—
EPS growth	178.7%	-5.5%	32.5%	-211.3%	178.7%	—
FCF growth	11.9%	-21.6%	5.9%	10.2%	-7.9%	—
PER SHARE ($)
EPS (diluted, TTM)	3.15	2.98	3.95	-4.39	3.46	4.55
Book value / share	16.20	14.62	14.48	8.02	9.05	10.93
Revenue / share	20.90	21.73	22.14	23.71	23.61	24.09
FCF / share	6.87	5.63	6.22	6.84	6.29	5.60
Cash / share	7.76	4.36	6.04	5.33	5.23	5.42
SHAREHOLDER RETURN & SCORES
Buyback yield	5.4%	6.0%	5.5%	0.0%	0.0%	0.08%
Altman Z-Score	2.10	2.44	2.21	1.46	2.18	2.7
Piotroski F-Score	8	5	6	4	8	7/9
Beneish M-Score	-2.77	-2.70	-2.70	-3.75	-2.95	-2.98

Model	Score	Zone	Note
Piotroski F-Score	7 / 9	Strong
Altman Z-Score	2.7	Grey zone	Grey
Income quality	1.38	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.98	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.78
Interest burden	0.91
Operating margin	26.6%
Asset turnover	0.54×
Financial leverage	4.59×
= ROE	47%

Growth Quality (live)	Value
Revenue stability	0.94
Earnings stability	0.17
Earnings persistence	0.50
Revenue CAGR 3y	2.9%
EPS CAGR 3y	6.2%
FCF CAGR 3y	2.2%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.08%

Dividend Yield4.22%

Total Shareholder Return4.43%cash yield

SBC / Revenue1.1%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
PFE	$168.6B	39.1	5%	-1.6%	-0.2%	7/9	+24.2%
GILD	$193.7B	-60.1	-21%	—	+5.5%	5/9	+33.4%
AMGN	$233.8B	26.7	91%	23.6%	+9.2%	8/9	+50.3%
AZN	$256.5B	24.7	22%	16.3%	+8.6%	9/9	-1.5%
NVS	$286.3B	22.9	31%	22.7%	+0.8%	5/9	—
MRK	$360.1B	115.8	7%	-8.0%	+4.5%	4/9	—
BIIB	$34.4B	41.0	5%	3.6%	-0.5%	3/9	—
ABBV	$504.4B	80.4	-206%	21.3%	+10.4%	7/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Hold

42 Analysts

Str Sell (0)Sell (2)Hold (21)Buy (19)Str Buy (0)

Mean Target (qtr)$65.5413 targets

Target vs. Price+9.7%last-quarter mean

Next Report2026-10-29street $1.09

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$49.89B	$50.15B / $49.15B	$6.32	$6.65 / $5.97	17
FY2027	$48.50B	$49.92B / $47.41B	$6.62	$7.42 / $6.12	17
FY2028	$41.00B	$44.73B / $36.34B	$5.41	$6.67 / $3.84	9

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$58.40	-2.3%	5
Last Quarter	$65.54	+9.7%	13
Last Year	$62.63	+4.8%	30
All Time	$65.02	+8.8%	59

Rolling mean of published targets vs. last close $59.75. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

A-

DCF

5/5

ROE

5/5

ROA

5/5

Debt/Eq

1/5

P/E

3/5

P/B

2/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

BMY +43.8% vs S&P 500 +15.9% — spread +28.0pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$60.35	-0.60	-0.99%	Below
SMA 50	$62.99	-3.24	-5.14%	Below
SMA 200	$58.48	+1.27	+2.17%	Above
EMA 9	$59.46	+0.29	+0.49%	Above
EMA 21	$60.43	-0.68	-1.13%	Below
EMA 50	$61.37	-1.62	-2.64%	Below
EMA 200	$58.01	+1.74	+3.00%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBEARISHPower Score -337 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%33

Momentum 25%40

Volume 20%31

Volatility 10%0

Patterns 15%50

This Week18% bullishof 11 price-based votes

4 Weeks Ago18%+0 pts since

12 Weeks Ago100%-82 pts since

ReadStabilizingweek-over-week trajectory

Price vs SMA 20$60.35

Price vs SMA 50$62.99

Price vs SMA 200$58.48

EMA 9/21 Cross59.5/60.4

SMA 50/200Golden

ADX DirectionADX 20

Supertrend$62

Parabolic SAR$56

SMA Slope-0.130

RSI45.5

Stochastic K/D51/36

StochRSI K/D81/52

Williams %R-51

CCI-9

TSI vs Signal-19.7

CMO-9.0

ROC-2.29%

OBV SignalDistrib

Chaikin MF-0.120

MFI33

Force Index-2M

Elder Ray Bull1.00

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 36

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$61.07 / $61.75 / $62.93	S1 / S2	$59.89 / $59.21
Bollinger (20,2)	$57.16 – $63.54	Squeeze	Off
52-wk range	$40.71 – $67.94	Off 52-wk high	-12.1%
ATR (14)	$1.77 (3.0%)	Historical vol	30.6%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

-2.0%Jan45%

+0.9%Feb60%

+2.3%Mar62%

-1.6%Apr45%

-0.2%May35%

+1.0%Jun60%

+0.2%Jul45%

-1.1%Aug65%

+1.4%Sep65%

+1.3%Oct45%

+2.2%Nov70%

+2.8%Dec70%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	BMY	S&P 500
Weekly volatility (σ, 1y)	3.06%	1.83%
Best / worst week (1y)	+7.1% / -7.6%	—
Max drawdown (5y, monthly)	-42.0%	—
1-week VaR (95%)	-5.6%	—
Beta (5y)	0.23	1.00

BMY EQUITY WEATHER (LIVE)RAINY · -35

Trend-31

Momentum-9

Volume-55

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 610 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall-34.6-25.0 vs industry

Trend-30.5-26.4 vs industry

Momentum-9.5-19.3 vs industry

Volume-55.0-71.6 vs industry

Reading	BMY	Drug Manufacturers - General n=150	Healthcare n=5,272	All US symbols n=70,435
Overall	-34.6	-9.5	-24.0	-20.5
Trend	-30.5	-4.1	-25.6	-21.3
Momentum	-9.5	+9.9	-28.5	-15.8
Volume	-55.0	+16.6	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Christopher S. Boerner, Ph.D. Board Chair an	$21.9M	91% equity+incentive
Samit Hirawat , M.D. Former EVP, Chief Medic	$10.3M	65% equity+incentive
Cristian Massacesi , M.D. EVP, Chief Medical	$10.1M	85% equity+incentive
Adam Lenkowsky EVP, Chief Commercialization	$9.3M	85% equity+incentive
David V. Elkins EVP and Chief Financial Offi	$9.2M	85% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	74
Social	65
Governance	71
Composite ESG	70

Composite ESG Trend

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-11-05 to 2026-07-30
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	123 rows · 1995 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-09-01 to 2026-10-02
Proposed sales (Form 144)	edgar/form144	not present for this symbol
Beneficial ownership (13D/G)	edgar/13dg	not present for this symbol
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Bristol-Myers Squibb Company (BMY)

Institutions holding — 12 quarters

Bristol-Myers Squibb Company (BMY)

Monthly Net Insider Flow (000 shares)

Signal Summary

Bristol-Myers Squibb Company (BMY)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding BMY — quarterly

Institutional Put/Call — quarterly

Where BMY Trades in the Dark

Bristol-Myers Squibb Company (BMY)

3.8 · Employees (SEC filings)

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

Balance Sheet — Full

Cash Flow Statement — Full

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

Street Price Target — Trajectory

Third-Party Composite Rating

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

Family Scores (site weights)

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)